Treatment with prasinezumab, a monoclonal antibody designed to break up toxic alpha-synuclein aggregates, failed to slow the progression of Parkinson’s disease in a Phase 2 clinical trial. “In this placebo-controlled trial, treatment with prasinezumab, a humanized monoclonal antibody targeting aggregated [alpha]-synuclein, had no meaningful effect on global clinical or…
Physical activity may be beneficial to brain health, including for people with neurodegenerative diseases such as Parkinson’s disease, by promoting increases in brain volume, a long-term follow-up study suggests. “Our study results indicate that even small behavioral changes, such as walking 15 minutes a day or taking the stairs…
Fluctuations in weight, either a loss or a gain, occurred significantly more often in people with Parkinson’s disease than in those without the progressive neurodegenerative disorder, a study has found. Weight loss in Parkinson’s patients was associated with a faster progression of motor and cognitive declines over a five-year…
A miniature antibody-like molecule called a nanobody effectively broke up toxic alpha-synuclein aggregates that are characteristic of Parkinson’s disease, and prevented the spread of these aggregates in the brains of mice in a disease model. The novel construct was described in the journal Nature Communications, in the study, “…
Treatment with Kynmobi (apomorphine hydrochloride), an approved under-the-tongue therapy for “off” episodes in Parkinson’s disease, does not substantially alter heartbeat dynamics at approved doses, according to new clinical trial data. The study, “A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s…
Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…
Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…
The Parkinson’s Foundation invested $1.1 million in two fellowships programs aimed at giving neurologists and nurse practitioners more specialized and expert training in Parkinson’s disease (PD). Specifically, the investment supports the Institutional Movement Disorder (IMDS) Fellowship Program for neurologists and the newly opened Nurse Practitioner (NP) Fellowship in Movement Disorders.
A new project by scientists at the University of Michigan (UM) aims to design a prototype autonomous vehicle that’s specifically designed to help meet the needs of people living with Parkinson’s disease. The project, called “Inclusive Design in Shared Autonomous Vehicles for People with Parkinson’s Disease,” is being funded…
A Parkinson’s-associated variant in the LRRK2 gene affects the gene’s activity in a single group of brain cells: microglia, the resident immune cells of the brain. “Our study demonstrates that cell type should be considered when evaluating the role of noncoding variation in disease pathogenesis [development],” the researchers wrote. The…
Get regular updates to your inbox.
